SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...